Media stories about G1 Therapeutics (NASDAQ:GTHX) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. G1 Therapeutics earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.2383636142193 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

GTHX has been the subject of a number of recent research reports. BidaskClub raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Cowen reissued a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. JPMorgan Chase & Co. lifted their price target on shares of G1 Therapeutics to $30.00 in a research report on Monday, February 5th. BTIG Research initiated coverage on shares of G1 Therapeutics in a research note on Tuesday, December 19th. They set a “buy” rating and a $38.00 price objective for the company. Finally, Zacks Investment Research lowered shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $32.80.

G1 Therapeutics (NASDAQ:GTHX) traded down $1.03 during trading hours on Friday, reaching $19.38. 123,260 shares of the company’s stock were exchanged, compared to its average volume of 65,261. G1 Therapeutics has a 1-year low of $12.04 and a 1-year high of $28.67.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. equities research analysts predict that G1 Therapeutics will post -2.72 earnings per share for the current year.

In other news, Director Fredric N. Eshelman acquired 250,000 shares of G1 Therapeutics stock in a transaction on Monday, November 13th. The stock was acquired at an average cost of $19.73 per share, for a total transaction of $4,932,500.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Medimmune Ventures, Inc. sold 133,906 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $19.75, for a total transaction of $2,644,643.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 546,682 shares of company stock valued at $10,865,628.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with's FREE daily email newsletter.